Enovis Corp ENOV
We take great care to ensure that the data presented and summarized in this overview for Enovis CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ENOV
View all-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.21MShares$169 Million0.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.11MShares$166 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.43MShares$148 Million0.01% of portfolio
-
American Century Companies Inc Kansas City, MO3.52MShares$95.8 Million0.09% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.93MShares$79.6 Million0.03% of portfolio
-
Davenport & CO LLC2.84MShares$77.3 Million0.52% of portfolio
-
Royce & Associates LP2.49MShares$67.7 Million1.09% of portfolio
-
State Street Corp Boston, MA1.89MShares$51.5 Million0.0% of portfolio
-
Diamond Hill Capital Management Inc Columbus, OH1.87MShares$50.9 Million0.34% of portfolio
-
Hood River Capital Management LLC Palm Beach Gardens, FL1.44MShares$39.2 Million1.05% of portfolio
Latest Institutional Activity in ENOV
Top Purchases
Top Sells
About ENOV
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
Insider Transactions at ENOV
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 30
2025
|
Angela S Lalor |
BUY
Grant, award, or other acquisition
|
Direct |
718
+3.38%
|
-
|
Jun 01
2025
|
Phillip Benjamin (Ben) Berry SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,013
-0.88%
|
$31,403
$31.3 P/Share
|
May 21
2025
|
A Clayton Perfall |
BUY
Grant, award, or other acquisition
|
Direct |
6,598
+12.83%
|
-
|
May 21
2025
|
Sharon L Wienbar |
BUY
Grant, award, or other acquisition
|
Direct |
6,598
+16.83%
|
-
|
May 21
2025
|
Brady Shirley |
BUY
Grant, award, or other acquisition
|
Direct |
6,598
+5.87%
|
-
|
May 21
2025
|
Liam Kelly |
BUY
Grant, award, or other acquisition
|
Direct |
6,598
+25.18%
|
-
|
May 21
2025
|
Rajiv Vinnakota |
BUY
Grant, award, or other acquisition
|
Direct |
6,598
+18.93%
|
-
|
May 21
2025
|
Angela S Lalor |
BUY
Grant, award, or other acquisition
|
Direct |
6,598
+24.96%
|
-
|
May 21
2025
|
Barbara W. Bodem |
BUY
Grant, award, or other acquisition
|
Direct |
6,598
+30.76%
|
-
|
May 21
2025
|
Christine Ortiz |
BUY
Grant, award, or other acquisition
|
Direct |
6,598
+30.76%
|
-
|
May 21
2025
|
Philip Okala |
BUY
Grant, award, or other acquisition
|
Direct |
6,598
+30.76%
|
-
|
May 12
2025
|
Phillip Benjamin (Ben) Berry SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
59,259
+33.96%
|
-
|
May 12
2025
|
Damien Mc Donald Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
96,296
+50.0%
|
-
|
Apr 01
2025
|
Brady Shirley |
BUY
Grant, award, or other acquisition
|
Direct |
829
+0.83%
|
-
|
Mar 31
2025
|
Angela S Lalor |
BUY
Grant, award, or other acquisition
|
Direct |
589
+4.26%
|
-
|
Mar 07
2025
|
Bradley J Tandy SVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,275
+24.77%
|
-
|
Mar 07
2025
|
Matthew L. Trerotola CEO |
BUY
Grant, award, or other acquisition
|
Direct |
94,135
+20.13%
|
-
|
Mar 07
2025
|
Terry D Ross GROUP PRESIDENT, P&R |
BUY
Grant, award, or other acquisition
|
Direct |
18,103
+33.39%
|
-
|
Mar 07
2025
|
John Kleckner Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,459
+30.82%
|
-
|
Mar 07
2025
|
Louis Vogt GROUP PRESIDENT, RECON |
BUY
Grant, award, or other acquisition
|
Direct |
15,086
+29.05%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 530K shares |
---|
Payment of exercise price or tax liability | 86.8K shares |
---|